ClinicalTrials.gg
Sign In
Not yet recruitingNCT07824232Updated Sep 17, 2026

Visual Function and Exercise in Glaucoma Patients

An observational study in Glaucoma and Exercise, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 100 Years
Sex
All
01

Study summary

This study will investigate the relationship between visual function-including central visual field, the retinal nerve fiber layer (RNFL) in the macular and optic disc regions, intraocular pressure, and other factors-and exercise in patients with glaucoma. It aims to explore whether exercise has a protective effect on visual function in glaucoma patients and to provide recommendations for the clinical care of these patients.

02

Conditions studied

  • Glaucoma
  • Exercise
03

In context

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 223 are open to participants now.

This study's planned enrollment of 100 is close to the median of 101 across 385 observational studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 182 studies on the registry; 108 are open to participants now.

Browse Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

glaucoma patients in Shanghai General Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-100 years male or female glaucoma patients
  • Complete the sports questionnaire

Exclusion criteria

Exclusion Criteria:

  • diseases that cause less than 5 years survival;
  • condition that causes low compliance, for instance cognition disorder;
  • Any eye with disease that would interfere with the examinations
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • questionnaire

    Other: answer questionnaire

Interventions

  • Otheranswer questionnaire

    All patients enrolled in the cohort are required to complete a questionnaire.

06

What researchers measure

Primary outcomes

  1. central visual field

    Time frame: month 3

Secondary outcomes

  1. retinal nerve fiber layer (RNFL) in the macular regions

    Time frame: month 3

  2. retinal nerve fiber layer (RNFL) in the optic disc regions

    Time frame: month 3

  3. intraocular pressure

    Time frame: month 3

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Of 110 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 3 months is below that.

Counting every sponsor, half of 134 studies reached it within 31 months; a quarter within 12 and three quarters within 208.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2026
First posted
Sep 17, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07824232
Lead sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Responsible party
Xiaodong Sun (Prof., Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Sep 17, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Sep 17, 2026

Study contacts

Guanran Zhang
Contact
guanranzhang@126.com
8615662690379
Xiaodong Sun
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Glaucoma →

Other studies from this sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine →

Start the discussion